VIAL
Compound comparison

Ipamorelin vs Sermorelin

Ipamorelin and Sermorelin are both peptide compounds evaluated on Vial: Ipamorelin is available as a compounded preparation with clinical-trial evidence, and Sermorelin is available as a compounded preparation with clinical-trial evidence, offered by 20 and 26 verified providers respectively.

Vial summary · compiled from public records

At a glance

Ipamorelin

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
20providers on Vial →

Sermorelin

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
26providers on Vial →

Side by side

FieldIpamorelinSermorelin
CategoryPeptidePeptide
Brand names
FDA / legal statusCompoundableCompoundable
Evidence tierClinical TrialsClinical Trials
Administration routeSubcutaneousSubcutaneous
Compounding accessAvailable through 503A and 503B compounding pharmaciesAvailable through 503A and 503B compounding pharmacies
Providers on Vial20 listed26 listed
Typical price band$$ to $$$$ to $$$

Verified providers offering each

Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+ High Confidence70 to 84 Well Documented50 to 69 Limited ConfidenceUnder 50 Flagged

About each compound

About Ipamorelin

A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.

About Sermorelin

A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.

Related compound comparisons

Other comparisons in the same category.

All compound comparisons →